10-Q: INmune Bio Reports Increased Losses Amidst Ongoing Clinical Trials

INmune Bio's Q2 2024 report reveals a significant increase in net losses and operating expenses, primarily driven by escalating research and development costs for its clinical programs.

Summary

• INmune Bio reported a net loss of $20.8 million for the six months ended June 30, 2024, compared to a $13.0 million loss for the same period in 2023.
• The company's operating expenses increased to $20.9 million for the first half of 2024, up from $12.9 million in the first half of 2023, with research and development expenses being the primary driver.
• Research and development expenses rose to $15.7 million for the first half of 2024, compared to $8.3 million in the first half of 2023, largely due to increased spending on the Alzheimer's clinical program.
• The company's cash and cash equivalents decreased to $31.1 million as of June 30, 2024, from $35.8 million at the end of 2023.
• INmune Bio is projecting insufficient liquidity to sustain operations through one year following the date the financial statements are issued, raising substantial doubt about its ability to continue as a going concern.
• The company is exploring various financing strategies, including public or private sales of equity, debt financing, and strategic alliances.
• The company completed two registered direct offerings in April 2024, raising approximately $13.4 million in net proceeds.
• The company is conducting Phase 2 trials for its Alzheimer's drug, XPro, and a Phase 1/2 trial for its cancer drug, INKmune.
• The company has terminated further enrollment in the MDS/AML trial due to recruitment difficulties.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses and concerns about the company's ability to continue as a going concern, which overshadows the progress in clinical trials. The need for additional capital raises and the termination of a clinical trial further contribute to a negative sentiment.

Positives

• The company successfully raised approximately $13.4 million in net proceeds through registered direct offerings in April 2024.
• The Phase II trial for XPro in early Alzheimer's disease is progressing with enrollment expected to be completed by mid-year.
• The Phase I/II trial for INKmune in metastatic castrate resistant prostate cancer is on track with recruitment.
• The company has identified potential accelerated approval pathways for XPro in the treatment of Alzheimer's disease.
• The company has a $2.9 million grant from the National Institute of Mental Health (NIMH) to treat treatment resistant depression (TRD) with XPro.

Negatives

• The company's net loss increased significantly to $20.8 million for the first half of 2024.
• The company's operating expenses have increased substantially, primarily due to increased research and development costs.
• The company's cash reserves have decreased to $31.1 million, raising concerns about its ability to continue as a going concern.
• The company is projecting insufficient liquidity to sustain operations through one year following the date the financial statements are issued.
• The company terminated further enrollment in the MDS/AML trial due to recruitment difficulties.
• The company has a significant accumulated deficit of $141.8 million.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to recurring losses and negative cash flows.
• The company may not be able to secure additional financing on favorable terms, or at all.
• The company's product candidates are still in development and may not receive regulatory approval or be commercially viable.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The company relies on a small number of vendors for manufacturing supplies and materials, which could be disrupted.
• The company's clinical trials may be delayed or unsuccessful.
• The company's intellectual property may not be adequately protected.
• The company's financial results could be adversely affected by fluctuations in foreign currency exchange rates.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues its research and development efforts and seeks regulatory approvals for its product candidates. The company is also exploring various financing strategies to fund its operations.

Management Comments

• Management is currently evaluating different strategies to obtain the required funding of future operations.
• Management believes that targeting cells of the innate immune system may make a therapeutic impact on many diseases.
• Management believes that neutralizing sTNF is a cornerstone to the treatment of these diseases.
• Management believes XPro targets activated microglia and astrocytes of the brain that produce sTNF that promotes nerve cell loss, synaptic dysfunction and prevents myelin repair.
• Management believes INKmune may be best used to eliminate residual disease after the patient has completed other cancer therapies.

Industry Context

The company operates in the competitive biotechnology industry, focusing on developing novel immunotherapies for cancer and neurodegenerative diseases. The company's approach of targeting the innate immune system and using precision medicine aligns with current trends in the industry. The company's focus on Alzheimer's disease and treatment-resistant depression addresses significant unmet medical needs.

Comparison to Industry Standards

• The company's increased R&D spending is typical for clinical-stage biotech companies, but the magnitude of the increase is significant.
• The company's cash burn rate is high, which is not uncommon for companies in this stage of development, but the company's cash runway is short.
• The company's reliance on equity and debt financing is standard for biotech companies, but the company's ability to secure additional funding is uncertain.
• The company's clinical trial progress is in line with industry timelines, but the success of these trials is not guaranteed.
• The company's approach to targeting sTNF is unique compared to traditional TNF inhibitors, which may provide a competitive advantage.
• The company's focus on biomarkers for patient selection in clinical trials is a growing trend in the industry.
• The company's termination of the MDS/AML trial due to recruitment difficulties is a common challenge in clinical research.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any pending legal proceedings that it believes will have a material adverse effect on its business or financial conditions.

Related Party Transactions

• The company had related party transactions with UCL for medical research.
• The company had related party transactions with AmplifyBio for medical research.
• The company has a license agreement with Immune Ventures, LLC, which is owned by the company's President, CFO, and CSO.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from future capital raises.
• Employees may be concerned about job security due to the company's financial challenges.
• Customers and partners may be hesitant to engage with the company due to its uncertain future.
• Creditors face increased risk of non-payment due to the company's financial difficulties.
• Suppliers may be concerned about the company's ability to pay for goods and services.

Next Steps

• The company plans to complete enrollment in the Phase II Alzheimer's trial by mid-year.
• The company plans to report top-line cognition data from the Phase II Alzheimer's trial six months after the last patient is enrolled.
• The company plans to have an end-of-phase II meeting with the FDA to finalize plans for the pivotal Phase III trial.
• The company plans to apply for an accelerated pathway for XPro during 2024.
• The company plans to submit for Fast Track status in 2024.
• The company expects to be eligible for Break Through status after completion of the Phase II trial in 2025.
• The company expects to receive authorization to initiate a clinical trial in TRD in the 2H24.
• The company expects the TRD trial to start enrollment after the AD Phase II trial finishes patient enrollment.
• The company expects to report data from each cohort of the INKmune prostate cancer trial as it becomes available.
• The company expects the Phase I portion of the INKmune prostate cancer trial to complete follow-up in September 2024.
• The company estimates the INKmune prostate cancer trial will be completely enrolled 1H25 with top-line data available 6 months later.

Key Dates

Keywords

Biotechnology, Clinical Trials, Immunotherapy, Alzheimer's Disease, Cancer, INmune Bio, XPro, INKmune, Research and Development, Financial Results